Abstract

Prolonged bisphosphonate therapy associated with atypical femoral fracture continues to occur. Protocols to avoid excessive duration of therapy should be utilised routinely. The importance of reviewing risk factors for fractures such as vitamin D status, interacting medications and management of comorbidities such as hemiplegic stroke with spasticity is highlighted.